



*pro*FLORA™


**Innovative and unique enhanced
probiotic action**





INTESTINAL ECOSYSTEM: "THE GUARDIAN OF THE BODY"

Apart from its primary function of nutrient absorption, the intestinal mucosa has also an important immune function. This is secondary to antigenic stress induced by food intake (with its microbial load) and by the presence of a **varied flora of resident microorganisms** (Microbiota) adhering to the intestinal walls or transient: ¹⁻²⁻³



Bacterial and physiochemical interactions in different areas of the gastro intestinal tract in adults (From: adapted from Gibson and Rastell)

It is estimated that about **98% of the population suffers from dysbiosis**, i.e. a depletion of beneficial microbial species: this leads to a series of bowel dysfunctions that may have a negative impact on the health conditions of individuals. ⁴⁻⁵⁻⁶⁻⁷⁻⁸⁻⁹



FROM GUNA RESEARCH STUDIES IN THE PROBIOTIC FIELD

NEW "MICRO-ENCAPSULATED" *pro*FLORA™

"ENHANCED" COLONY-FORMING ACTION
TO REBALANCE THE ECOSYSTEM OF THE DIFFERENT BOWEL TRACTS



TECHNOLOGICAL INNOVATION

6 PROBIOTIC STRAINS (LACTOBACILLI AND BIFIDOBACTERIA) IN GASTRO-PROTECTED MICRO-ENCAPSULATED FORM

- ✓ The use of a natural coating for the process of **microencapsulation** significantly **improves** the **survival capacity** and the **resistance** of all probiotic strains during the gastroduodenal transit and digestive processes.¹⁰⁻¹¹
- ✓ **100%** of the **alive and viable** probiotic strains reach the different tracts of the intestine, **for the maximum documented activity of colonization**:

"It was shown "in vivo" that the colonization kinetics of 1×10^9 /CFU of probiotics in a "gastro protected micro-encapsulated" form is comparable to that of 5×10^9 /CFU of non micro-encapsulated probiotics".*

* Del Piano M. *et Al.* – Evaluation of the intestinal colonization by micro-encapsulated probiotic bacteria in comparison with the same uncoated strains. – J. Clin. Gastroenterol. 2010 Sept; 44 Suppl 1:S42-6. Double blind study.



*pro*FLORA™ PREBIOTIC AND PROBIOTIC SYNERGY



Proflora™ is **allergen free tested**. Patented by Probiotal S.p.A., i.e., it is free of ALL allergens according to current legislation (Annex II Reg. EU 1169/2011): wheat, rye, barley, oats, spelt, kamut and hybridised strains, crustaceans and products based on shellfish, eggs and egg products, fish and seafood, peanuts, soy and soy products, milk and dairy including lactose, nuts, celery, mustard, sesame seeds, lupins, molluscs and products based on molluscs, sulfur dioxide and sulphites at concentrations above 10 mg / kg or 10 mg / liter.

BENEFITS

- ➔ **6 selected probiotics strains**, in “gastro-protected micro-encapsulated” form, for maximum probiotic biological activity:
 - ✓ *Bifidobacterium lactis* BS01, *Lactobacillus acidophilus* LA02 and *Lactobacillus paracasei* LPC00: 3 specific strains for an effective colonization of the intestine
 - ✓ *Bifidobacterium lactis* BS01, *Lactobacillus acidophilus* LA02 and *Lactobacillus paracasei* LPC00: 3 specific strains for an effective colonization of the intestine
 - ✓ *Lactobacillus rhamnosus* LR06 and *Lactobacillus plantarum* LP02: specific to counteract the spread of coliform bacteria (*Escherichia coli*)
- ➔ **Enhanced ability to restore** the intestinal environment and function
- ➔ **Fructo-oligosaccharides (FOS)** are associated to probiotic strains, for an effective synergy.
- ➔ **easy to use**



THE 6 "GASTRO-PROTECTED" MICROENCAPSULATED STRAINS OF proFLORA™ : (content per sachet)

• <i>Bifidobacterium lactis</i> BS01	> 1.00 billion B
• <i>Lactobacillus acidophilus</i> LA02	> 0.25 billion B
• <i>Lactobacillus paracasei</i> LPC00	> 0.25 billion B
• <i>Lactobacillus rhamnosus</i> LR06	> 0.25 billion B
• <i>Lactobacillus plantarum</i> LP02	> 0.25 billion B
• <i>Lactobacillus salivarius</i> LS03	> 0.02 billion B


FOR A TOTAL OF NO LESS THAN 2 BILLION ALIVE
AND VIABLE CELLS PER SACHET

- ✓ Each of the six microbial species, belonging to the genus *Bifidobacterium* and *Lactobacillus*, are "gastro-protected" and act in synergy for a **higher effectiveness and colonization of the different intestinal segments**.

The effect continues over time thanks to a high ability to adhere to the intestinal mucosa, due to the action of *Lactobacillus salivarius* LS03.

- ✓ The micro-encapsulated probiotic strains of Proflora™ include *Lactobacillus rhamnosus* LR06 and *Lactobacillus plantarum* LP02. They are both able to produce **active substances (bacteriocins) that limit the spread of coliform bacteria in various intestinal segments**. That's why Proflora™ is especially recommended for subjects with frequent episodes of infections of the genitourinary tract due to *Escherichia coli*:

Bacteria responsible for urinary tract infections



FRUCTO-OLIGOSACCHARIDES (FOS) WITH CERTIFIED PREBIOTIC ACTIVITY

Derived from sugar beet, **FOS** contained in Proflora are not hydrolyzed by digestive enzymes nor absorbed by the mucosa of the small intestine, and succeed in reaching intact the colon where they **are able to selectively stimulate the development of probiotic strains present in Proflora™ and of all beneficial microbial groups of Lactobacilli and Bifidobacteria of the resident microflora**.


The **FOS** have a positive role in the carbohydrate and fat metabolism, **improve** the function of the intestinal mucosa by increasing the "barrier" effect, and **facilitate** the absorption of certain minerals, especially **calcium** and **magnesium**.



GASTRO-PROTECTED MICRO-ENCAPSULATED

NUTRITION FACTS		
	per sachet (2.5 g)	per 100 g
Energy	28.26 kJ 6.75 kcal	1130 kJ 270 kcal
Fat	17.6 mg	0.7 g
of which saturates	7.8 mg	0.31 g
Carbohydrate	2336.5 mg	93.46 g
of which sugars	958 mg	38.32 g
Fibre	1380 mg	55.20 g
Protein	2 mg	0.08 g
Salt	1 mg	0.04 g
<ul style="list-style-type: none"> <i>Bifidobacterium lactis</i> BS01 <i>Lactobacillus rhamnosus</i> LR06 <i>Lactobacillus paracasei</i> LPC00 <i>Lactobacillus acidophilus</i> LA02 <i>Lactobacillus plantarum</i> LP02 <i>Lactobacillus salivarius</i> LS03 	> 1.00 B * > 0.25 B * > 0.25 B * > 0.25 B * > 0.25 B * > 0.02 B *	> 40 B * > 10 B * > 10 B * > 10 B * > 10 B * > 0.8 B *
Fructo-oligosaccharides FOS	1500 mg	60 g

- ➔ Proflora™ is recommended for:
 - ✓ children, the elderly, pregnant and breast feeding women
 - ✓ allergic, celiac subjects or with the most diverse food intolerances
- ➔ **100% alive and viable** probiotic content of over 2 billion/ sachet, guaranteed until expiration date.
- ➔ Certification and traceability (abbreviation: BS-LR-LP-LS) of probiotic strains registered in an International Culture Collection
- ➔ The stability and survival of the strains is guaranteed during production and storage, and for the entire shelf life.
- ➔ Odorless



Lactobacillus rhamnosus
LR06-DSM 21981



Bifidobacterium lactis
BS01-LMG P-21384



Lactobacillus acidophilus
LA02-DSM 21717



proFLORA™ PREBIOTIC AND PROBIOTIC SYNERGY

A HEALTHY SUPPORT IN CASE OF:

- Antibiotic and/or laxative treatments
- Diarrhea
- Gastrointestinal disorders
- Digestive difficulties
- Irritable colon
- Uro-genital infections
- Respiratory allergies
- Adverse reactions to foods
- Abdominal bloating
- Meteorism
- Mental and physical stress

INSTRUCTIONS FOR USE

Adults and children:

1 sachet daily for periods of 30 consecutive days.





In cases of acute symptoms:

Adults and children:

1 to 2 sachets daily for 8-10 days depending on the symptoms.

Take **preferably half an hour before meals**: pour the content of one sachet, then add **half a glass of water or milk**, stir well and **drink immediately**.

THE MOST COMMON ASSOCIATIONS

ASSOCIATIONS	INDICATIONS
<p>PROFLORA™ + COLOSTRO NONI</p> 	<p>Protection of the intestinal mucosa Supportive gastro-intestinal treatment Supportive treatment of respiratory allergies Supportive treatment of acute and chronic cystitis Adverse reactions to food</p>
<p>PROFLORA™ + VIT FORMULA™</p> 	<p>Vitamin and mineral malabsorption</p>
<p>PROFLORA™ + FERROGUNA</p> 	<p>Supportive treatment of iron deficiency anemia</p>
<p>PROFLORA™ + GUNAELMINT</p> 	<p>Recovery of the intestinal microflora to prevent or treat helminth infestation</p>



The content of alive and viable microorganisms is guaranteed until the expiration date stated on the label

KEY WORDS:

Unique and innovative enhanced "micro-encapsulated" synbiotic for the natural rebalancing of the ecosystem of the different tracts of the intestine

Ingredients

Fructo-oligosaccharides (FOS); Maltodextrin; **Gastro-protected micro-encapsulated probiotics:** *Bifidobacterium lactis* BS01 (LMG P-21384), *Lactobacillus acidophilus* LA02 (DSM 21717), *Lactobacillus paracasei* LPC00 (LMG P-21380), *Lactobacillus plantarum* LP02 (LMG P-21020), *Lactobacillus rhamnosus* LR06 (DSM 21981), *Lactobacillus salivarius* LS03 (DSM 22776); Anti-caking agent: silicon dioxide.

Storage conditions

Store in a dry place, away from direct light and at a temperature not exceeding 25° C.

Warnings

The expiry date refers to a product correctly stored in its original and undamaged packing. Do not exceed the stated recommended daily dose. Keep out of reach of young children. Food supplements should not intended as a substitute for a varied diet and a healthy lifestyle.

Packaging

10 sachets. Net weight 25 g.
30 sachets. Net weight 75 g.

References

1. Bottazzi V. – Il Microbiota Intestinale. Università degli Studi di Milano; Pubblicazione Mofin Alce **2009**.
2. Faria A.M., Weiner H.L. – Oral tolerance: mechanisms and therapeutic applications. *Adv. Immunol.* 73: 153-264; **1999**.
3. Guarner F., Malagelada J.R. – Gut flora in health and disease. *Lancet* **2003**; 361: 512-19.
4. Heine H. – Medicina omotossicologica e regolazione di base: reazione immunologica di soccorso. *La Med. Biol.* **1998**/4; 9-12.
5. Neutra M.R. – Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. *Am. J. Physiol. Gastrointest. Liver Physiol.* 274: G785-G791; **1998**.
6. Perugini F. – Il sistema immunitario associato alle mucose (MALT) e la Medicina Biologica. *La Med. Biol.* **1996**/4; 27-31.
7. Pilette C., Ouadrhiri Y., Godding V., Vaerman J.P., Sibille Y. – Lung mucosal immunity: immunoglobulin-A revisited. *Eur Respir J*; 18 (3): 571-588 **2001**.
8. Shanahan F. – Transforming Growth Factor- β as a Regulator of Site-Specific T-Cell Inflammatory Response. *Am. J. Physiol. Gastrointest. Liver Physiol.* 278: G191-G196; **2000**.
9. Strober W.B., Marth T. – Oral tolerance. *J. Clin. Immunol.* 18: 1-30, **1998**.
10. Del Piano M. et Al. – In vitro Sensitivity of Probiotics to Human Pancreatic Juice. *J Clin Gastroenterol.* **2008**; 42(3): S170-173.
11. Charteris W.P. et Al. – Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic *Lactobacillus* and *Bifidobacterium* species in the upper human gastrointestinal tract. *J Appl Microbiol.* **1998**; 84(5):759-768.



GUNA S.p.a.

Via Palmanova, 71 - 20132 MILAN - ITALY
tel. +39 02 280181 - fax +39 02 28018449
www.gunainc.com - e-mail: export@guna.it
www.gunainternational.com